van Mens LJJ, et al. - Researchers investigated the efficacy of the combination of golimumab plus methotrexate (MTX) vs MTX alone as a first-line treatment in inducing remission in psoriatic arthritis (PsA). In this investigator-initiated, multicentre, double-blind, randomized, placebo-controlled trial, they randomized 51 MTX and bDMARD-naive patients with PsA fulfilling the CASPAR criteria and with active disease at baseline (≥3 swollen joint count/tender joint count), to golimumab (50 mg SC monthly)+MTX (n=26) (TNFi arm) or matched placebo+MTX (n=25) (MTX arm). Golimumab+MTX in patients with early PsA led to almost double Disease Activity Score (DAS) remission at week 22 vs MTX alone. Outcomes thereby support that in patients with PsA, early initiation of TNFi favors remission.